iShares' IYH or Invesco's PBE: Which Healthcare ETF Is the Better Long-Term Buy?
Broad diversification and lower costs favor iShares, but Invesco's concentrated biotech bet delivered 47% returns in one year—at the cost of steeper drawdowns.
Overview
The iShares U.S. Healthcare ETF (NYSEMKT:IYH) provides broad sector exposure at a lower cost, while the Invesco Biotechnology & Genome ETF (NYSEMKT:PBE) offers a concentrated, high-conviction bet on genomics.
Investors seeking healthcare exposure often choose between broad industry coverage and niche subsectors. This comparison pits the wide-reaching iShares fund against the specialized Invesco biotech fund to determine which approach fits a portfolio's risk tolerance and growth objectives as of Aug. 28, 2026.
Details
Beta measures price volatility relative to the S&P 500; beta is calculated from monthly returns over the available fund history (up to five years). The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.
Source
Originally published at www.fool.com.